PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population

Japanese pharma Kyowa Kirin has been granted approval from the European Commission for Crysvita in older adolescents and adults with X-linked hypophosphataemia (XLH).

Crysvita (burosumab) is already approved in the EU for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older and adolescents with growing skeletons.

The expanded approval for Crysvita is based on data from two phase III studies in adults with XLH as well in adults with XLH-associated osteomalacia (softening of the bones).

These studies found that treatment with Crysvita increased and maintained serum phosphate levels in the normal range, helped to heal pseudofractures and fractures related to osteomalacia and improved osteomalacia.

Additional endpoints demonstrated that patients had less pain and stiffness and their physical functioning and mobility also improved with time.

“Today’s decision from the European Commission is a significant milestone for the management of XLH, a progressive and life-long disease that profoundly impacts the lives of both children and adults,” said Abdul Mullick, president of Kyowa Kirin International.

With this approval, older adolescents and adults with XLH will also be able to benefit from treatment with CRYSVITA, the only therapy that targets the underlying pathophysiology of this disease. We now will focus on ensuring access for as many people as possible in this expanded group of eligible patients,” he added.

XLH is a progressive disease that causes lower limb deformities, stunted growth and joint pain. Other symptoms, including dental abscesses, osteoarthritis, enthesopathy and hearing loss can also develop during adulthood.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026